-
Data showed that Somatuline® statistically significantly prolonged time to disease progression or death in non-functioning GEP-NET patients (p=0.0002; hazard ratio 0.47; 95% CI: 0.30–0.73)
-
After 2 years of treatment with Somatuline®, disease progression or death was reduced by 53%: 62% of GEP-NET patients treated with Somatuline® had not progressed or died versus 22% with placebo
-
Pre-specified subgroup analyses showed that the antiproliferative effect of Somatuline® is statistically significant in midgut tumors, clinically relevant in pancreatic NETs and independent of the tumor grade and hepatic tumor load
-
Safety data generated from the study are consistent with known safety profile of Somatuline®
PARIS, France I September 28, 2013 I Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the results of the CLARINET® study were presented on Saturday 28 September at the 2013 European Cancer Congress in Amsterdam. The results were presented in the LBA3 abstract: “A randomized, double-blind, placebo-Controlled study of Lanreotide Antiproliferative Response in patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET)”.
Primary endpoint
CLARINET® met its primary endpoint by demonstrating that treatment with Somatuline® Autogel® / Somatuline® Depot® (lanreotide) Injection 120 mg (referred to as Somatuline®) was associated with a statistically significant reduction of the risk of disease progression or death by 53% vs. placebo (hazard ratio 0.47, 95% CI: 0.30–0.73; p=0.0002). This result is based on the observation that 62% of GEP-NET patients treated with Somatuline® had not progressed or died versus 22% with placebo over the follow-up period (Kaplan-Meier estimates). The median progression free survival was not reached (beyond 2 years) in the Somatuline® group versus 18 months in the placebo group.
Pr Martyn Caplin, Professor of Gastroenterology & Gastrointestinal Neuroendocrinology, Royal Free Hospital (London, UK) and Principal Investigator of CLARINET®, commented: “The CLARINET® study presents compelling data regarding the antiproliferative effect of Somatuline® in gastroentero and pancreatic neuroendocrine tumors. This is the first report from a prospective, double-blind trial showing increased PFS with a SSA in the treatment of non-functioning GEP-NETs. Importantly, the subgroup analysis showed statistically significant benefit in patients with midgut tumors, with well to moderately differentiated tumors and with tumors with high hepatic load”.
Claude Bertrand, Executive Vice-President Research & Development and Chief Scientific Officer of Ipsen commented: “CLARINET® is the first large-scale, multinational, phase III trial to demonstrate the antiproliferative effect of Somatuline®, Ipsen’s long-acting somatostatin analog, in patients with non-functioning GEP-NETs. We are pleased with the robust results demonstrated in the study, which adds to the available data regarding treatment of gastroentero and pancreatic neuroendocrine tumors”.
Subgroup analysis
The effect of Somatuline® on disease progression was observed across certain pre-specified subgroups of patients. Statistically significant results were obtained in patients with midgut tumors, in patients with G1 and G2 (proliferation index Ki67 <10%) tumors, and in patients with moderate (≤ 25%) and high (>25%) hepatic tumor load.
The data on Somatuline® with respect to progression free survival showed a clinically relevant difference vs placebo in patients with pancreatic NETs, although the subgroup analysis did not reach statistical significance.
The results per subgroup are disclosed in the table below:
| Subgroups |
|
|
Progression free survival (PFS) |
|
|
Statistical results |
|
|
| Midgut NETs (n=73) |
|
|
Median PFS:
- Somatuline®: > 2 years
- Placebo: 21.1 months
|
|
|
- hazard ratio 0.35
- 95% CI: 0.16 -0.80
- p=0.0091
|
|
|
| Pancreatic NETs (n=91) |
|
|
Median PFS:
- Somatuline®: > 2 years
- Placebo: 12.1 months
|
|
|
- hazard ratio 0.58
- 95% CI: 0.32 -1.04
- p=0.0637
|
|
|
| WHO grade tumors: G1 (n=141) |
|
|
Median PFS:
- Somatuline®: > 2 years
- Placebo: 18.3 months
|
|
|
- hazard ratio 0.43
- 95% CI: 0.25 -0.74
- p=0.0016
|
|
|
| WHO grade tumors: G2 (n=61) |
|
|
Median PFS:
- Somatuline®: > 2 years
- Placebo: 12.1 months
|
|
|
- hazard ratio 0.45
- 95% CI: 0.22 -0.91
- p=0.0235
|
|
|
| Hepatic tumor load (≤ 25%) (n=133) |
|
|
Median PFS:
- Somatuline®: > 2 years
- Placebo: 21.1 months
|
|
|
- hazard ratio 0.34
- 95% CI: 0.18 -0.62
- p=0.0002
|
|
|
| Hepatic tumor load (> 25%) (n=67) |
|
|
Median PFS:
- Somatuline®: 24.1 months
- Placebo: 9.4 months
|
|
|
- hazard ratio 0.45
- 95% CI: 0.23 – 0.88
- p=0.0170
|
|
|
Safety profile
Safety data generated from the CLARINET® study were consistent with the known safety profile of Somatuline®. Treatment-related adverse events occurred in 50% of patients treated with Somatuline® versus 28% in the placebo arm, and very few of these were serious (3% with Somatuline® versus 1% with placebo). The most frequent treatment-related adverse events included diarrhea (26% with Somatuline® versus 9% with placebo), abdominal pain (14% with Somatuline® vs 2% with placebo) and gallstone formation (10% with Somatuline® vs 3 % with placebo).
The data from CLARINET® is considered investigational, as Somatuline® is not approved specifically to treat non-functioning GEP-NETs in any market. Somatuline® is approved for treatment of symptoms associated with neuroendocrine tumors, which can include the treatment of GEP-NETs patients experiencing symptoms from carcinoid syndrome, in many markets where it is marketed as Somatuline® Autogel®. Somatuline® is not approved in the US to treat neuroendocrine tumors or symptoms thereof, where it is marketed as Somatuline® Depot®.
About CLARINET®
CLARINET® is a randomized, double-blind, placebo-Controlled study of Lanreotide Antiproliferative Response in patients with non-functioning gastroenteropancreatic NeuroEndocrine Tumours (ClinicalTrials.gov NCT00353496). This 96-week multinational study was conducted in collaboration with UK & Ireland Neuroendocrine Tumour Society (UKI NETS) as well as the European Neuroendocrine Tumour Society (ENETS).
A total of 265 patients from 44 centres across 14 countries were enrolled, with 204 patients with well or moderately differentiated non-functioning GEP-NETs and a proliferation index (Ki67) of <10%, subsequently randomly allocated to treatment (n=101 in Somatuline® Autogel® 120 mg group and n=103 in placebo group). At enrollment, primary tumor locations were pancreas (44%), midgut (36%), hindgut (7%) and unknown (13%). Most patients had stable tumors (96%) and were treatment-naïve (84%). 30% of patients had Ki67 3%–10% (WHO grade 2), 33% had hepatic tumor load >25%.
The primary endpoint of efficacy was time to either disease progression (using Response Evaluation Criteria In Solid Tumors, RECIST) or death. Two baseline computed tomography scans (≥12 weeks apart) were performed, followed by additional scans at 12 weeks intervals during the first year and 24 weeks intervals during the second year up to 96 weeks.
About gastroenteropancreatic neuroendocrine tumors
Gastroentero and pancreatic neuroendocrine tumors (GEP-NETs) are rare but their incidence is increasing. They constitute a heterogeneous group of tumors with location of the primary tumor in the gastric mucosa, pancreas, small and large intestine. GEP-NETs when they are functioning secrete hormones and neuroamines that cause distinct clinical symptoms, such as the carcinoid syndrome associating diarrhea and flushing. However, non-functioning GEP-NETs do not secrete hormones and can remain clinically silent, delaying the diagnosis until late presentation with symptoms like weight loss or related to mass effects such as abdominal pain.
About Somatuline®
The active substance in Somatuline® is lanreotide acetate, a somatostatin analogue that inhibits the secretion of several endocrine, exocrine and paracrine functions. It has been shown to be effective in inhibiting the secretion of GH and certain hormones secreted by the digestive system. Somatuline® is marketed as Somatuline® Depot® within the United States and as Somatuline® Autogel® in other countries where it has marketing authorization.
Somatuline® was initially developed and continues to be used for the treatment of acromegaly in many countries, including the United States, where it is indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. Somatuline® is not indicated for its antiproliferative effect on GEP-NETs. Somatuline® is approved for the treatment of symptoms associated with neuroendocrine tumors in many markets, but is not approved within the United States for this indication.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totalled close to €250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
SOURCE: Ipsen
Post Views: 197
-
Data showed that Somatuline® statistically significantly prolonged time to disease progression or death in non-functioning GEP-NET patients (p=0.0002; hazard ratio 0.47; 95% CI: 0.30–0.73)
-
After 2 years of treatment with Somatuline®, disease progression or death was reduced by 53%: 62% of GEP-NET patients treated with Somatuline® had not progressed or died versus 22% with placebo
-
Pre-specified subgroup analyses showed that the antiproliferative effect of Somatuline® is statistically significant in midgut tumors, clinically relevant in pancreatic NETs and independent of the tumor grade and hepatic tumor load
-
Safety data generated from the study are consistent with known safety profile of Somatuline®
PARIS, France I September 28, 2013 I Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the results of the CLARINET® study were presented on Saturday 28 September at the 2013 European Cancer Congress in Amsterdam. The results were presented in the LBA3 abstract: “A randomized, double-blind, placebo-Controlled study of Lanreotide Antiproliferative Response in patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET)”.
Primary endpoint
CLARINET® met its primary endpoint by demonstrating that treatment with Somatuline® Autogel® / Somatuline® Depot® (lanreotide) Injection 120 mg (referred to as Somatuline®) was associated with a statistically significant reduction of the risk of disease progression or death by 53% vs. placebo (hazard ratio 0.47, 95% CI: 0.30–0.73; p=0.0002). This result is based on the observation that 62% of GEP-NET patients treated with Somatuline® had not progressed or died versus 22% with placebo over the follow-up period (Kaplan-Meier estimates). The median progression free survival was not reached (beyond 2 years) in the Somatuline® group versus 18 months in the placebo group.
Pr Martyn Caplin, Professor of Gastroenterology & Gastrointestinal Neuroendocrinology, Royal Free Hospital (London, UK) and Principal Investigator of CLARINET®, commented: “The CLARINET® study presents compelling data regarding the antiproliferative effect of Somatuline® in gastroentero and pancreatic neuroendocrine tumors. This is the first report from a prospective, double-blind trial showing increased PFS with a SSA in the treatment of non-functioning GEP-NETs. Importantly, the subgroup analysis showed statistically significant benefit in patients with midgut tumors, with well to moderately differentiated tumors and with tumors with high hepatic load”.
Claude Bertrand, Executive Vice-President Research & Development and Chief Scientific Officer of Ipsen commented: “CLARINET® is the first large-scale, multinational, phase III trial to demonstrate the antiproliferative effect of Somatuline®, Ipsen’s long-acting somatostatin analog, in patients with non-functioning GEP-NETs. We are pleased with the robust results demonstrated in the study, which adds to the available data regarding treatment of gastroentero and pancreatic neuroendocrine tumors”.
Subgroup analysis
The effect of Somatuline® on disease progression was observed across certain pre-specified subgroups of patients. Statistically significant results were obtained in patients with midgut tumors, in patients with G1 and G2 (proliferation index Ki67 <10%) tumors, and in patients with moderate (≤ 25%) and high (>25%) hepatic tumor load.
The data on Somatuline® with respect to progression free survival showed a clinically relevant difference vs placebo in patients with pancreatic NETs, although the subgroup analysis did not reach statistical significance.
The results per subgroup are disclosed in the table below:
| Subgroups |
|
|
Progression free survival (PFS) |
|
|
Statistical results |
|
|
| Midgut NETs (n=73) |
|
|
Median PFS:
- Somatuline®: > 2 years
- Placebo: 21.1 months
|
|
|
- hazard ratio 0.35
- 95% CI: 0.16 -0.80
- p=0.0091
|
|
|
| Pancreatic NETs (n=91) |
|
|
Median PFS:
- Somatuline®: > 2 years
- Placebo: 12.1 months
|
|
|
- hazard ratio 0.58
- 95% CI: 0.32 -1.04
- p=0.0637
|
|
|
| WHO grade tumors: G1 (n=141) |
|
|
Median PFS:
- Somatuline®: > 2 years
- Placebo: 18.3 months
|
|
|
- hazard ratio 0.43
- 95% CI: 0.25 -0.74
- p=0.0016
|
|
|
| WHO grade tumors: G2 (n=61) |
|
|
Median PFS:
- Somatuline®: > 2 years
- Placebo: 12.1 months
|
|
|
- hazard ratio 0.45
- 95% CI: 0.22 -0.91
- p=0.0235
|
|
|
| Hepatic tumor load (≤ 25%) (n=133) |
|
|
Median PFS:
- Somatuline®: > 2 years
- Placebo: 21.1 months
|
|
|
- hazard ratio 0.34
- 95% CI: 0.18 -0.62
- p=0.0002
|
|
|
| Hepatic tumor load (> 25%) (n=67) |
|
|
Median PFS:
- Somatuline®: 24.1 months
- Placebo: 9.4 months
|
|
|
- hazard ratio 0.45
- 95% CI: 0.23 – 0.88
- p=0.0170
|
|
|
Safety profile
Safety data generated from the CLARINET® study were consistent with the known safety profile of Somatuline®. Treatment-related adverse events occurred in 50% of patients treated with Somatuline® versus 28% in the placebo arm, and very few of these were serious (3% with Somatuline® versus 1% with placebo). The most frequent treatment-related adverse events included diarrhea (26% with Somatuline® versus 9% with placebo), abdominal pain (14% with Somatuline® vs 2% with placebo) and gallstone formation (10% with Somatuline® vs 3 % with placebo).
The data from CLARINET® is considered investigational, as Somatuline® is not approved specifically to treat non-functioning GEP-NETs in any market. Somatuline® is approved for treatment of symptoms associated with neuroendocrine tumors, which can include the treatment of GEP-NETs patients experiencing symptoms from carcinoid syndrome, in many markets where it is marketed as Somatuline® Autogel®. Somatuline® is not approved in the US to treat neuroendocrine tumors or symptoms thereof, where it is marketed as Somatuline® Depot®.
About CLARINET®
CLARINET® is a randomized, double-blind, placebo-Controlled study of Lanreotide Antiproliferative Response in patients with non-functioning gastroenteropancreatic NeuroEndocrine Tumours (ClinicalTrials.gov NCT00353496). This 96-week multinational study was conducted in collaboration with UK & Ireland Neuroendocrine Tumour Society (UKI NETS) as well as the European Neuroendocrine Tumour Society (ENETS).
A total of 265 patients from 44 centres across 14 countries were enrolled, with 204 patients with well or moderately differentiated non-functioning GEP-NETs and a proliferation index (Ki67) of <10%, subsequently randomly allocated to treatment (n=101 in Somatuline® Autogel® 120 mg group and n=103 in placebo group). At enrollment, primary tumor locations were pancreas (44%), midgut (36%), hindgut (7%) and unknown (13%). Most patients had stable tumors (96%) and were treatment-naïve (84%). 30% of patients had Ki67 3%–10% (WHO grade 2), 33% had hepatic tumor load >25%.
The primary endpoint of efficacy was time to either disease progression (using Response Evaluation Criteria In Solid Tumors, RECIST) or death. Two baseline computed tomography scans (≥12 weeks apart) were performed, followed by additional scans at 12 weeks intervals during the first year and 24 weeks intervals during the second year up to 96 weeks.
About gastroenteropancreatic neuroendocrine tumors
Gastroentero and pancreatic neuroendocrine tumors (GEP-NETs) are rare but their incidence is increasing. They constitute a heterogeneous group of tumors with location of the primary tumor in the gastric mucosa, pancreas, small and large intestine. GEP-NETs when they are functioning secrete hormones and neuroamines that cause distinct clinical symptoms, such as the carcinoid syndrome associating diarrhea and flushing. However, non-functioning GEP-NETs do not secrete hormones and can remain clinically silent, delaying the diagnosis until late presentation with symptoms like weight loss or related to mass effects such as abdominal pain.
About Somatuline®
The active substance in Somatuline® is lanreotide acetate, a somatostatin analogue that inhibits the secretion of several endocrine, exocrine and paracrine functions. It has been shown to be effective in inhibiting the secretion of GH and certain hormones secreted by the digestive system. Somatuline® is marketed as Somatuline® Depot® within the United States and as Somatuline® Autogel® in other countries where it has marketing authorization.
Somatuline® was initially developed and continues to be used for the treatment of acromegaly in many countries, including the United States, where it is indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. Somatuline® is not indicated for its antiproliferative effect on GEP-NETs. Somatuline® is approved for the treatment of symptoms associated with neuroendocrine tumors in many markets, but is not approved within the United States for this indication.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totalled close to €250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
SOURCE: Ipsen
Post Views: 197
